A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/64 (2006.01) A61K 31/00 (2006.01) A61K 38/17 (2006.01) A61K 39/395 (2006.01) A61K 45/06 (2006.01) A61K 48/00 (2006.01)
Patent
CA 2618099
The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NC ca-ATp channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NC ca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.
Gerzanich Vladimir
Simard J. Marc
Borden Ladner Gervais Llp
University Of Maryland Baltimore
LandOfFree
Antagonists of a non-selective cation channel in neural cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of a non-selective cation channel in neural cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of a non-selective cation channel in neural cells will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1912720